RxDoctor Payments Data

Steven Madsen

Dermatology · Cromwell, CTNPI 1861925356

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 29.6% of the total. 2025 is the largest year on record at $4,204, more than ten times the $74 reported in 2019.

$10,894in general payments, 2019–2025

Across 408 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$928
  • Pfizer$919
  • Novartis$736
  • LEO Pharma Inc.$729
  • Regeneron Healthcare Solutions, Inc.$625
  • plus $4K from 17 others

What the payments were for

  • Food & beverage$10,61697%
  • Education$2793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,894 in reported general payments places this provider in the 70th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$118,033
Medicare patients
349
Services billed
1,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$222,455
Dupixent PenDupilumab26$105,599
Clobetasol Propionate83$2,537
Betamethasone Dipropionate50$2,392
Ketoconazole196$2,230
Fluorouracil25$1,570
Triamcinolone Acetonide140$1,274
Calcipotriene13$1,001
Minoxidil46$524
Hydrocortisone62$413
Doxycycline Monohydrate24$333
Doxycycline Hyclate22$318
ValacyclovirValacyclovir Hcl12$244
Mupirocin22$152
Prednisone15$57

Paid to pharmacies, not to this prescriber.

Other dermatology in Cromwell

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →